Come meet Daniel Teper, PharmD, MBA, the Co-Founder, Chairman & Chief Executive Officer, of Cytovia Therapeutics, a company that aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer. Cytovia focuses on harnessing the innate immune system by developing complementary and disruptive iPSC-derived Natural Killer (iNK) cell and Flex-NK™ bispecific antibody platforms. The company is developing three types of iNK cells: unedited iNK cells, TALEN® gene-edited iNK cells with improved function and persistence, and TALEN® gene-edited iNK cells with chimeric antigen receptors (CAR-iNKs) to improve tumor-specific targeting. The second complementary cornerstone technology is a quadrivalent multifunctional antibody platform designed to engage natural killer cells by targeting NKp46 using Cytovia's proprietary Flex-NK™ technology.

These two technology platforms are being used to develop treatment for patients with solid tumors such as HCC and glioblastoma as well as hematological malignancies such as refractory multiple myeloma. Headquartered in Aventura, FL., Cytovia has research and development laboratories in Natick, MA. The company's own R&D work is augmented through scientific partnerships with Cellectis, CytoImmune, the Hebrew University of Jerusalem, INSERM, the New York Stem Cell Foundation, the National Cancer Institute, and the University of California San Francisco (UCSF).

Cytovia has developed a partnership with CytoLynx Therapeutics focused on research and development, manufacturing, and commercialization activities in Greater China and beyond.

Find out more at www.cytoviatx.com 

Learn More

Sonoma Pharmaceuticals (NASDAQ: SNOA) is a specialty pharmaceutical company dedicated to identifying, developing and commercializing unique, affordable differentiated therapies and branded prescription products to improve the lives of patients with dermatologic diseases and conditions and advanced tissue care needs. The Company’s products, which are sold throughout the United States and in 39 countries around the world, have improved patient outcomes for more than five million patients globally by treating and reducing certain topical skin diseases and conditions including acne, atopic dermatitis, scarring, infections, itch, pain, odor and harmful inflammatory responses. The Company’s headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. In 2013, with a new Board of Directors and new management team, the Company pivoted to focus on one specialty pharmaceutical area, medical dermatology, and created their own sales force in the United States to promote their unique, affordable, differentiated prescription dermatology products. Their customer base includes hospitals, medical centers, doctors, pharmacies, distributors and wholesalers. The Company sells products directly to end users and to distributors. The Company also licenses its technology and products.

Finjan, founded in 1996, is a diversified technology company.  Finjan's engineers and developers pioneered behavior-based, real-time detection of online threats, and the company's patents cover core functionality and features used in modern security architectures.  Finjan operates four distinct business units:

• An IP licensing business leverages a host of patents through its subsidiaries Finjan, Inc, Finjan Mobile and Finjan Blue. 
• The VitalSecurity™ platform protects consumer mobile devices in the workplace while securing personal and corporate data.
• CyberRisk™ Security Solutions Ltd. provides bespoke risk assessment and cyber security consulting services to satisfy corporations’ compliance and governance needs.
• Finjan also incubates up-and-coming technology startups pioneering a new generation of security technologies through its investment in Jerusalem Venture Partners (JVP) innovation funds.

Fate Therapeutics (NASDAQ: FATE) is developing clinical-stage cellular immunotherapies for cancer and immune disorders, with an opportunity in 2017 to broadly establish the leading NK (natural killer) cell clinical franchise. The Company’s programs include:

• A first-in-class adaptive memory NK cell product candidate (FATE-NK100) designed to enhance direct tumor cell killing, resist immune checkpoints and promote endogenous T-cell anti-tumor response.
  • Investigational New Drug (IND) cleared by FDA for initiation of clinical investigation in acute myelogenous leukemia (AML)
• A next-generation mobilized peripheral blood graft (ProTmune) for the prevention of graft-versus-host disease (GvHD) in patients with hematologic malignancies undergoing transplant
  • Phase 1/2 PROTECT study ongoing
  • ProTmune granted FDA Fast Track and Orphan Drug designations
• A human induced pluripotent stem cell (iPSC) platform that enables the generation of master cell lines to renewably create off-the-shelf engineered NK- and T-cell cancer immunotherapies
  • Collaborations with University of Minnesota and Memorial Sloan Kettering for product candidate development

The Company raised $57 million in Nov 2016 from a leading investor syndicate including Redmile Group LLC, BVF Partners L.P., EcoR1 Capital LLC, and Franklin Advisers, Inc., and had approximately $100 million in cash following the financing.  Institutional ownership exceeds 70%.

First Majestic (NYSE: AG) is a mining company focused on silver production in Mexico and is aggressively pursuing the development of its existing mineral property assets. The Company presently owns and operates six producing silver mines; the La Parrilla Silver Mine, the San Martin Silver Mine, the La Encantada Silver Mine, the La Guitarra Silver Mine, Del Toro Silver Mine and the Santa Elena Silver Mine . Production from these six mines is anticipated to be between 10.0 to 10.6 million ounces of pure silver or 15.7 to 16.6 million ounces of silver equivalents in 2017.

Learn More

Hecla Mining Company (NYSE: HL) is a precious metals company. Their business is to create value for their shareholders by discovering, acquiring, developing, producing, and marketing mineral resources at a profit. Their mission is to create long-term value for shareholders from mining silver, gold and associated base metals.

Learn More

Bio-Path Holdings (NASDAQ: BPTH) is a clinical stage biotechnology company developing therapeutics for the treatment of cancer and systemic diseases. Bio-Path's RNAi technology for drug development, DNAbilize™, uses a novel liposomal antisense DNA platform that allows for systemic delivery of nucleic acids without toxicity. Using DNAbilize™ clinicians can inhibit the production of proteins involved in cancer and block pathways involved in disease progression.  
 

COMPANY HIGHLIGHTS

• Proprietary antisense and liposome delivery technology breakthrough for DNA drugs, potentially solving the challenges of delivering these molecules directly to target cells without side effects
• Original technology licensed from The MD Anderson Cancer Center. Company maintains strong relationship with the Cancer Center
• Strong IP position with composition of matter and method patents for antisense targets and manufacturing
• Lead product candidate, prexigebersen (Liposomal Grb2) formerly BP1001, in the clinic for blood cancers and in development for solid tumors. Second product candidate, BP1002 (Liposomal Bcl2) is IND-ready
• Promising clinical data for BP1001 shows that the drug has been well tolerated with possible anti-leukemic effects, including patients stabilizing for extended treatment

Learn More